Biohit Oyj

BIOBV

FI0009005482

Office Equipment

Market Closed - Nasdaq Helsinki Other stock markets 10:45:35 2024-04-26 am EDT			5-day change	1st Jan Change
2.02 ^EUR	+1.25%		-1.46%	+7.16%

Apr. 15	Faron Pharmaceuticals reappoints former finance chief on interim basis	AN
Feb. 14	Biohit Oyj Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Biohit Oyj - Managers' Transactions Panu Hendolin

August 25, 2023 at 07:01 am EDT

Person subject to the notification requirement

Name: Panu Hendolin

Position: Other senior manager

Issuer: Biohit Oyj

LEI: 74370089ATTSNBXJVT29

Notification type: INITIAL NOTIFICATION

Reference number: 37028/6/6

____________________________________________

Transaction date: 2023-08-23

Venue: NASDAQ HELSINKI LTD (XHEL)

Instrument type: SHARE

ISIN: FI0009005482

Nature of transaction: ACQUISITION

Transaction details

(1): Volume: 400 Unit price: 2 EUR

Aggregated transactions (1):

Volume: 400 Volume weighted average price: 2 EUR

____________________________________________

Transaction date: 2023-08-24

Venue: NASDAQ HELSINKI LTD (XHEL)

Instrument type: SHARE

ISIN: FI0009005482

Nature of transaction: DISPOSAL

Transaction details

(1): Volume: 7 Unit price: 1.98 EUR

(2): Volume: 200 Unit price: 1.97 EUR

(3): Volume: 310 Unit price: 2 EUR

(4): Volume: 456 Unit price: 1.99 EUR

(5): Volume: 800 Unit price: 1.98 EUR

(6): Volume: 1450 Unit price: 1.98 EUR

Aggregated transactions (6):

Volume: 3223 Volume weighted average price: 1.98272 EUR

CEO Jussi Hahtela, Biohit Oyj

tel. +358 9 773861
investor.relations@biohit.fi
www.biohithealthcare.com

https://news.cision.com/biohit-oyj/r/biohit-oyj---managers--transactions-panu-hendolin,c3823952

https://mb.cision.com/Main/18502/3823952/2252870.pdf

Latest news about Biohit Oyj

Faron Pharmaceuticals reappoints former finance chief on interim basis	Apr. 15	AN
Biohit Oyj Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 14	CI
Biohit Names New Chief Commercial Officer	Nov. 22	MT
Biohit Oyj Provides Earnings Guidance for the Period from 2024 to 2028	Nov. 22	CI
Biohit Oyj Announces Changes in the Management Group	Nov. 22	CI
Biohit Revises Earnings Guidance for 2023	23-08-09	CI
Biohit Oyj Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-09	CI
Biohit Oyj Elects Vesa Silaskivi as Chairman of the Board of Directors	23-06-15	CI
Biohit Oyj Approves Election of Vesa Silaskivi as Members of Board of Directors	23-06-14	CI
Biohit Oyj Provides Earnings Guidance for the Year 2023	23-02-15	CI
Biohit Oyj Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-15	CI
Biohit Oyj Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-15	CI
Biohit Oyj Announces Executive Changes	22-12-15	CI
Biohit Appoints New CFO	22-09-06	MT
Biohit Oyj Appoints Jussi Sorvo as Chief Financial Officer, Effective on September 7, 2022	22-09-06	CI
Biohit Oyj Appoints Jussi Sorvo as Member of the Management, Effective on September 7, 2022	22-09-06	CI
Finnish Biotech Biohit Appoints CFO as CEO	22-09-02	MT
Biohit Oyj Announces Executive Changes	22-09-02	CI
Biohit Oyj Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-10	CI
Biohit Oyj Revises Earnings Guidance for the Year 2022	22-08-03	CI
Biohit Oyj Appoints Lea Paloheimo as the Chairman of the Board of Directors	22-06-16	CI
Biohit Oyj Elects Kalle Härkönen as Board of Director	22-06-15	CI
Biohit Oyj Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-16	CI
Biohit Oyj Provides Earnings Guidance for the Year 2022	22-02-16	CI
Biohit Oyj Specifies Financial Guidance for 2021	22-02-08	CI

Biohit Oyj is a Finland-based company engaged in the development, manufacture and marketing of diagnostic tests and analysis systems. The Company operates one business segment, named Diagnostics. The Diagnostics segment offers solutions for the early diagnosis and prevention of gastrointestinal diseases. It provides blood-sample examination based on GastroPanel for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, as well as the ColonView examination for the early detection of fecal occult intestinal bleeding, which indicates a risk of colorectal cancer. The Companyâs products are used in hospitals, healthcare centers and research institutions. It operates primarily in Europe and Asia. Furthermore, the Company is a parent of Biohit Healthcare Ltd, Biohit Healthcare Srl, Oy Finio Ab, and Vantaan Hienomekano Oy, among others.

Sector

Office Equipment

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Biohit Oyj

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.02 EUR

Average target price

2.4 EUR

Spread / Average Target

+18.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Scientific & Precision Equipment

	1st Jan change	Capi.
BIOHIT OYJ	+7.16%	32.72M
SHIMADZU CORPORATION	+7.13%	7.91B
TECAN GROUP AG	-3.15%	4.66B
OLINK HOLDING AB	-9.18%	2.84B
JEOL LTD.	+1.11%	2.03B
NINGBO YONGXIN OPTICS CO.,LTD	-26.56%	1.12B
ECKERT & ZIEGLER SE	-11.09%	816M
PARK SYSTEMS CORP.	-13.49%	755M
FOCUSED PHOTONICS (HANGZHOU), INC.	-22.71%	759M
MLOPTIC CORP.	-56.85%	682M

Scientific & Precision Equipment

Biohit Oyj

Equities

BIOBV

FI0009005482

Office Equipment

Biohit Oyj - Managers' Transactions Panu Hendolin

Latest news about Biohit Oyj

Chart Biohit Oyj

Company Profile

Income Statement Evolution

Ratings for Biohit Oyj

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Scientific & Precision Equipment